985 related articles for article (PubMed ID: 14633671)
1. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
[TBL] [Abstract][Full Text] [Related]
2. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
[TBL] [Abstract][Full Text] [Related]
3. Antitumor effect of 5-aminolevulinic acid-mediated photodynamic therapy can be enhanced by the use of a low dose of photofrin in human tumor xenografts.
Peng Q; Warloe T; Moan J; Godal A; Apricena F; Giercksky KE; Nesland JM
Cancer Res; 2001 Aug; 61(15):5824-32. PubMed ID: 11479222
[TBL] [Abstract][Full Text] [Related]
4. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
Ching LM; Goldsmith D; Joseph WR; Körner H; Sedgwick JD; Baguley BC
Cancer Res; 1999 Jul; 59(14):3304-7. PubMed ID: 10416582
[TBL] [Abstract][Full Text] [Related]
5. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
Joseph WR; Cao Z; Mountjoy KG; Marshall ES; Baguley BC; Ching LM
Cancer Res; 1999 Feb; 59(3):633-8. PubMed ID: 9973211
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
[TBL] [Abstract][Full Text] [Related]
7. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
Browne WL; Wilson WR; Baguley BC; Ching LM
Anticancer Res; 1998; 18(6A):4409-13. PubMed ID: 9891501
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of photodynamic therapy antitumor activity in mice by nitric oxide synthase inhibition is fluence rate dependent.
Henderson BW; Sitnik-Busch TM; Vaughan LA
Photochem Photobiol; 1999 Jul; 70(1):64-71. PubMed ID: 10420844
[TBL] [Abstract][Full Text] [Related]
9. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
10. Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Cao Z; Baguley BC; Ching LM
Cancer Res; 2001 Feb; 61(4):1517-21. PubMed ID: 11245459
[TBL] [Abstract][Full Text] [Related]
11. Celecoxib and NS-398 enhance photodynamic therapy by increasing in vitro apoptosis and decreasing in vivo inflammatory and angiogenic factors.
Ferrario A; Fisher AM; Rucker N; Gomer CJ
Cancer Res; 2005 Oct; 65(20):9473-8. PubMed ID: 16230411
[TBL] [Abstract][Full Text] [Related]
12. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
13. Improvement of the antitumor activity of intraperitoneally and orally administered 5,6-dimethylxanthenone-4-acetic acid by optimal scheduling.
Zhao L; Ching LM; Kestell P; Baguley BC
Clin Cancer Res; 2003 Dec; 9(17):6545-50. PubMed ID: 14695159
[TBL] [Abstract][Full Text] [Related]
14. Consequences of increased vascular permeability induced by treatment of mice with 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and thalidomide.
Chung F; Liu J; Ching LM; Baguley BC
Cancer Chemother Pharmacol; 2008 Mar; 61(3):497-502. PubMed ID: 17473922
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effect of photodynamic therapy in mice using direct application of Photofrin dissolved in lidocaine jelly.
Murakami H; Kohno E; Kohmura Y; Ozawa H; Ito H; Sugihara K; Horiuchi K; Hirano T; Kanayama N
Photodermatol Photoimmunol Photomed; 2009 Oct; 25(5):259-63. PubMed ID: 19747245
[TBL] [Abstract][Full Text] [Related]
16. The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy.
Sitnik TM; Henderson BW
Photochem Photobiol; 1998 Apr; 67(4):462-6. PubMed ID: 9559590
[TBL] [Abstract][Full Text] [Related]
17. Schedule-dependent interaction between Doxorubicin and mTHPC-mediated photodynamic therapy in murine hepatoma in vitro and in vivo.
Kirveliene V; Grazeliene G; Dabkeviciene D; Micke I; Kirvelis D; Juodka B; Didziapetriene J
Cancer Chemother Pharmacol; 2006 Jan; 57(1):65-72. PubMed ID: 16001168
[TBL] [Abstract][Full Text] [Related]
18. Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response.
Korbelik M; Sun J; Cecic I
Cancer Res; 2005 Feb; 65(3):1018-26. PubMed ID: 15705903
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response.
Ferrario A; Von Tiehl K; Wong S; Luna M; Gomer CJ
Cancer Res; 2002 Jul; 62(14):3956-61. PubMed ID: 12124326
[TBL] [Abstract][Full Text] [Related]
20. Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor.
Chung F; Wang LC; Kestell P; Baguley BC; Ching LM
Cancer Chemother Pharmacol; 2004 May; 53(5):377-83. PubMed ID: 15060740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
